Formycon (ETR:FYB) H1 2024 results

Key financial results

• Sales: €26.9 million (39% less than in the first half of 2023).

• Net loss: €10.1 million (compared to €1.80 million profit in the first half of 2023).

• €0.58 loss per share (after €0.11 profit in the first half of 2023).

All figures shown in the graph above refer to the last 12 months (TTM)

Formycon Earnings Insights

An average sales growth of 33% per annum is expected for the next three years. In the European biotechnology industry, however, growth of 20% is forecast.

Development of the market in Germany.

The company’s share price remained largely unchanged compared to the previous week.

Evaluation

Our analysis of Formycon based on 6 different valuation metrics shows that the company may be undervalued. Click here to find out what a fair price for the stock might be and what price performance analysts expect over the next year.

Do you have feedback on this article? Are you concerned about the content? Contact us directly from us. Alternatively, send an email to editorial-team (at) simplywallst.com.

This Simply Wall St article is of a general nature. We comment solely on the basis of historical data and analyst forecasts, using an unbiased methodology. Our articles do not constitute financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide you with long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St does not hold any of the stocks mentioned.